HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (50) Citing Articles via Google Scholar Google Scholar Articles by Halleen, J. M. Articles by Väänänen, H. K. Search for Related Content PubMed PubMed Citation Articles by Halleen, J. M. Articles by Väänänen, H. K. Related Collections Proteomics and Protein Markers

Serum Tartrate-resistant Acid Phosphatase 5b Is a Specific and Sensitive Marker of Bone Resorption

¹ Institute of Biomedicine, Department of Anatomy, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland

² Special Hematology Laboratory, Veterans Affairs Medical Center, Louisville, KY 40206

³ Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030-6145

⁴ Department of Medicine I, University of Heidelberg, 69115 Heidelberg, Germany
^a author for correspondence: fax 358-2-3337352, e-mail jushal@utu.fi

Bone-resorbing osteoclasts and activated macrophages express high amounts of type 5 tartrate-resistant acid phosphatase (TRACP; EC 3.1.3.2) (1). Osteoclasts secrete TRACP into the circulation, and serum TRACP has been considered a potentially useful marker of bone resorption. Several technical problems have prevented the use of serum TRACP as a specific marker of bone resorption. Early enzymatic assays lacked specificity because of the presence of interfering acid phosphatases derived from platelets and erythrocytes (2)(3). Serum TRACP can be determined by use of fluoride (4) or by immunoassays with antibodies specific for TRACP (5)(6)(7)(8)(9). However, there are two forms of TRACP in the serum, namely TRACP 5a and TRACP 5b. Of these, TRACP 5b is derived from osteoclasts, whereas TRACP 5a originates from other, as yet unidentified sources (10)(11)(12).

Two diagnostic assays have been developed recently for serum TRACP 5b: a kinetic assay based on the use of specific inhibitors (13), and an immunoassay based on a highly characterized specific monoclonal antibody (12). The TRACP 5b-specific immunoassay has been shown to be a useful method for monitoring antiresorptive therapy (12). We have now further characterized the immunoassay by studying the clinical specificity and clinical sensitivity of serum TRACP 5b in various bone diseases and nonskeletal diseases.

We obtained serum samples from 303 individuals after written informed consent. At the time of sampling, none of the subjects was receiving antiosteoporotic treatment. Healthy premenopausal women, healthy postmenopausal women, and breast cancer (BC) patients without evidence of bone metastases (BC-) . . . [Full Text of this Article]

Acknowledgments

References

The following articles in journals at HighWire Press have cited this article:

				Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428. [Abstract] [Full Text] [PDF]

				M. Herrmann, T. Widmann, G. Colaianni, S. Colucci, A. Zallone, and W. Herrmann Increased Osteoclast Activity in the Presence of Increased Homocysteine Concentrations Clin. Chem., December 1, 2005; 51(12): 2348 - 2353. [Abstract] [Full Text] [PDF]

				K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885. [Abstract] [Full Text] [PDF]

				T.-Y. Chao, J.-C. Yu, C.-H. Ku, M. M. Chen, S.-H. Lee, A. J. Janckila, and L. T. Yam Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Extensive Bone Metastasis in Breast Cancer Patients Clin. Cancer Res., January 15, 2005; 11(2): 544 - 550. [Abstract] [Full Text] [PDF]

				S. L. Alatalo, K. K. Ivaska, S. G. Waguespack, M. J. Econs, H. K. Vaananen, and J. M. Halleen Osteoclast-Derived Serum Tartrate-Resistant Acid Phosphatase 5b in Albers-Schonberg Disease (Type II Autosomal Dominant Osteopetrosis) Clin. Chem., May 1, 2004; 50(5): 883 - 890. [Abstract] [Full Text] [PDF]

				S. G. Waguespack, S. L. Hui, K. E. White, K. A. Buckwalter, and M. J. Econs Measurement of Tartrate-Resistant Acid Phosphatase and the Brain Isoenzyme of Creatine Kinase Accurately Diagnoses Type II Autosomal Dominant Osteopetrosis but Does Not Identify Gene Carriers J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2212 - 2217. [Abstract] [Full Text] [PDF]